Masimo Corporation (FRA:3M4)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.18B +13.9% |
| Revenue (ttm) | 1.35B +9.2% |
| Net Income | 66.21M |
| EPS | 1.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 155.00 |
| Previous Close | 155.00 |
| Day's Range | 155.00 - 155.00 |
| 52-Week Range | 108.20 - 156.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Masimo
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also pro... [Read more]
Financial Performance
In fiscal year 2025, Masimo's revenue was $1.53 billion, an increase of 9.44% compared to the previous year's $1.40 billion. Losses were -$151.50 million, -50.31% less than in 2024.
Financial numbers in USD Financial StatementsNews
Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner
IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--Masimo smartSET™-powered, AI-enabled OIRD detection has received FDA 510(k) clearance for the Radius VSM® wearable continuous patient monitor.
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...
Masimo Transcript: EGM 2026
Shareholders approved the merger with Danaher and an advisory compensation proposal. The CEO highlighted strategic achievements and the benefits of joining Danaher, with Masimo to remain an independent operating company within Danaher's diagnostics sector.
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--A NICU study evaluating Masimo SET® pulse oximetry on hospitalized newborns found no clinically significant differences in accuracy across skin tones.
Masimo Proxy statement: Proxy filing
Masimo filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Masimo Proxy statement: Proxy filing
Masimo filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Masimo Proxy statement: Proxy Filing
Masimo filed a proxy statement on March 18, 2026, providing details for shareholder voting and corporate governance matters.
Masimo Annual report: Q4 2025
Masimo has published its Q4 2025 annual report on February 27, 2026.
Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
What's Happening With Masimo Stock?
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only p...
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.
Masimo to be Acquired by Danaher for $180.00 Per Share
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Dan...
Danaher To Acquire Masimo Corporation
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo ...
Masimo Proxy statement: Proxy Filing
Masimo filed a proxy statement on February 17, 2026, providing details for shareholder voting and corporate governance matters.
Masimo Proxy statement: Proxy Filing
Masimo filed a proxy statement on February 17, 2026, providing details for shareholder voting and corporate governance matters.
Masimo Proxy statement: Proxy Filing
Masimo filed a proxy statement on February 17, 2026, providing details for shareholder voting and corporate governance matters.
Danaher Strikes $10 Billion Deal for Masimo
The medical-device maker is expected to operate as a stand-alone company within Danaher's Diagnostics segment.
This Medical-Devices Stock Is Soaring. It Could Be in Line for an Acquisition.
Masimo stock jumped on a report of a potential acquisition. The company is perhaps best known for its yearslong patent dispute with Apple.
Danaher closes in on nearly $10 billion deal for Masimo, FT reports
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter...
Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, Febru...
Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD...
Masimo Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financial performance and margin expansion were achieved, with a clear strategy for 7%-10% annual growth through U.S. and international market share gains, advanced monitoring, and new product launches. AI-driven innovation and partnerships underpin a robust pipeline, while organizational momentum sets the stage for continued success.
Masimo Announces Select Preliminary 2025 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Q...
Masimo to Present in the J.P. Morgan 2026 Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pa...